CN103539860A - 一种长效重组人促卵泡激素融合蛋白 - Google Patents
一种长效重组人促卵泡激素融合蛋白 Download PDFInfo
- Publication number
- CN103539860A CN103539860A CN201310529896.8A CN201310529896A CN103539860A CN 103539860 A CN103539860 A CN 103539860A CN 201310529896 A CN201310529896 A CN 201310529896A CN 103539860 A CN103539860 A CN 103539860A
- Authority
- CN
- China
- Prior art keywords
- hfsh
- fusion rotein
- restructuring
- cell
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract description 7
- 102000037865 fusion proteins Human genes 0.000 title abstract description 7
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 claims abstract description 115
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 claims abstract description 115
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 41
- 238000006471 dimerization reaction Methods 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 10
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 230000004927 fusion Effects 0.000 claims description 108
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 44
- 210000001672 ovary Anatomy 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 11
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 8
- 241000699802 Cricetulus griseus Species 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 239000013613 expression plasmid Substances 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000003151 transfection method Methods 0.000 claims description 6
- 102000015872 Human beta Subunit Chorionic Gonadotropin Human genes 0.000 claims description 5
- 108010010590 Human beta Subunit Chorionic Gonadotropin Proteins 0.000 claims description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- OVRNDRQMDRJTHS-ZTVVOAFPSA-N N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-ZTVVOAFPSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 102220315697 rs1553622313 Human genes 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims description 2
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 claims description 2
- 239000012617 Butyl Sepharose™ 4 Fast Flow Substances 0.000 claims description 2
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000001638 lipofection Methods 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 101710135378 pH 6 antigen Proteins 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 108020001096 dihydrofolate reductase Proteins 0.000 claims 1
- 208000021267 infertility disease Diseases 0.000 claims 1
- -1 more preferably Proteins 0.000 claims 1
- 210000001938 protoplast Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 33
- 238000001727 in vivo Methods 0.000 abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 10
- 208000000509 infertility Diseases 0.000 abstract description 5
- 230000036512 infertility Effects 0.000 abstract description 5
- 231100000535 infertility Toxicity 0.000 abstract description 5
- 101800005309 Carboxy-terminal peptide Proteins 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 229940027941 immunoglobulin g Drugs 0.000 abstract 2
- 241000700159 Rattus Species 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 24
- 206010003445 Ascites Diseases 0.000 description 15
- 238000010254 subcutaneous injection Methods 0.000 description 14
- 239000007929 subcutaneous injection Substances 0.000 description 14
- 230000009466 transformation Effects 0.000 description 12
- 239000013642 negative control Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000012173 estrus Effects 0.000 description 9
- 230000013595 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 102000057593 human F8 Human genes 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 7
- 229940047431 recombinate Drugs 0.000 description 7
- 101150074155 DHFR gene Proteins 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229940105423 erythropoietin Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005336 cracking Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 230000016087 ovulation Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000011121 vaginal smear Methods 0.000 description 5
- 108010084455 Zeocin Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000002513 anti-ovulatory effect Effects 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000005396 glutamine synthetase Human genes 0.000 description 2
- 108020002326 glutamine synthetase Proteins 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JDQXMGODAZSTHH-HNPMAXIBSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione;pyrimidine Chemical compound C1=CN=CN=C1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 JDQXMGODAZSTHH-HNPMAXIBSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000026234 pro-estrus Effects 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529896.8A CN103539860B (zh) | 2013-11-01 | 2013-11-01 | 一种长效重组人促卵泡激素融合蛋白 |
US15/033,286 US10023624B2 (en) | 2013-11-01 | 2014-08-22 | Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein |
PCT/CN2014/085010 WO2015062349A1 (zh) | 2013-11-01 | 2014-08-22 | 一种长效重组人促卵泡激素融合蛋白 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529896.8A CN103539860B (zh) | 2013-11-01 | 2013-11-01 | 一种长效重组人促卵泡激素融合蛋白 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103539860A true CN103539860A (zh) | 2014-01-29 |
CN103539860B CN103539860B (zh) | 2014-12-03 |
Family
ID=49963755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310529896.8A Active CN103539860B (zh) | 2013-11-01 | 2013-11-01 | 一种长效重组人促卵泡激素融合蛋白 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10023624B2 (zh) |
CN (1) | CN103539860B (zh) |
WO (1) | WO2015062349A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015062349A1 (zh) * | 2013-11-01 | 2015-05-07 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
WO2015062350A1 (zh) * | 2013-11-01 | 2015-05-07 | 广州联康医药科技有限公司 | 一种长效重组促卵泡激素及其应用 |
WO2018032785A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | 人成纤维细胞生长因子21融合蛋白及其制备方法与用途 |
WO2019051954A1 (zh) * | 2017-09-15 | 2019-03-21 | 北京伟杰信生物科技有限公司 | 长效重组猪fsh融合蛋白及其制备方法与应用 |
CN113336831A (zh) * | 2020-07-24 | 2021-09-03 | 上海延立药业有限公司 | 一种用于开发新冠病毒疫苗的长效重组糖蛋白 |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
CN114807231A (zh) * | 2022-06-28 | 2022-07-29 | 鲁东大学 | 鱼类促卵泡激素体细胞基因转移载体及其构建方法和应用 |
US11471513B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676096B (zh) * | 2018-05-22 | 2022-03-29 | 北京伟杰信生物科技有限公司 | 重组猪fsh-ctp融合蛋白及其制备方法与应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1131952A (zh) * | 1994-08-12 | 1996-09-25 | 华盛顿大学 | 糖蛋白激素四成员家族的单链形式 |
CN1309567A (zh) * | 1998-07-23 | 2001-08-22 | 伊莱利利公司 | Fsh和fsh变体制剂,产品和方法 |
CN1847265A (zh) * | 2005-04-15 | 2006-10-18 | 上海市计划生育科学研究所 | 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途 |
CN101087805A (zh) * | 2004-11-09 | 2007-12-12 | 阿雷斯贸易股份有限公司 | Fsh的纯化方法 |
CN101720332A (zh) * | 2007-06-28 | 2010-06-02 | 拜奥吉耐里克斯股份公司 | 生产促卵泡激素的细胞克隆 |
CN102448979A (zh) * | 2009-04-01 | 2012-05-09 | 拜奥吉耐里克斯股份公司 | 纯化重组促卵泡激素的方法 |
CN102786589A (zh) * | 2012-07-30 | 2012-11-21 | 南昌市万华生化药业有限公司 | 重组人促卵泡成熟素rFSH及其基因工程菌株 |
CN103059125A (zh) * | 2012-12-27 | 2013-04-24 | 浙江海正药业股份有限公司 | 重组人促卵泡激素的纯化方法 |
CN103159860A (zh) * | 2013-04-07 | 2013-06-19 | 旭华(上海)生物研发中心有限公司 | 重组组织型纤溶酶原激活剂及其制备方法与用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0461200T3 (da) * | 1989-02-21 | 1997-03-10 | Univ Washington | Modificerede former af reproduktionshormoner |
US6238890B1 (en) * | 1994-02-18 | 2001-05-29 | Washington University | Single chain forms of the glycoprotein hormone quartet |
US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
US7081446B2 (en) * | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
WO2005058953A2 (en) | 2003-12-12 | 2005-06-30 | Regeneron Pharmaceuticals, Inc. | Ogh fusion polypeptides and therapeutic uses thereof |
EP1711610A2 (en) * | 2004-01-28 | 2006-10-18 | Syntonix Pharmaceuticals, Inc. | HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY |
CN103539860B (zh) * | 2013-11-01 | 2014-12-03 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
CN103539862B (zh) | 2013-11-01 | 2015-04-01 | 广州联康生物科技有限公司 | 一种长效重组促卵泡激素及其应用 |
-
2013
- 2013-11-01 CN CN201310529896.8A patent/CN103539860B/zh active Active
-
2014
- 2014-08-22 WO PCT/CN2014/085010 patent/WO2015062349A1/zh active Application Filing
- 2014-08-22 US US15/033,286 patent/US10023624B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1131952A (zh) * | 1994-08-12 | 1996-09-25 | 华盛顿大学 | 糖蛋白激素四成员家族的单链形式 |
CN1309567A (zh) * | 1998-07-23 | 2001-08-22 | 伊莱利利公司 | Fsh和fsh变体制剂,产品和方法 |
CN101087805A (zh) * | 2004-11-09 | 2007-12-12 | 阿雷斯贸易股份有限公司 | Fsh的纯化方法 |
CN1847265A (zh) * | 2005-04-15 | 2006-10-18 | 上海市计划生育科学研究所 | 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途 |
CN101720332A (zh) * | 2007-06-28 | 2010-06-02 | 拜奥吉耐里克斯股份公司 | 生产促卵泡激素的细胞克隆 |
CN102448979A (zh) * | 2009-04-01 | 2012-05-09 | 拜奥吉耐里克斯股份公司 | 纯化重组促卵泡激素的方法 |
CN102786589A (zh) * | 2012-07-30 | 2012-11-21 | 南昌市万华生化药业有限公司 | 重组人促卵泡成熟素rFSH及其基因工程菌株 |
CN103059125A (zh) * | 2012-12-27 | 2013-04-24 | 浙江海正药业股份有限公司 | 重组人促卵泡激素的纯化方法 |
CN103159860A (zh) * | 2013-04-07 | 2013-06-19 | 旭华(上海)生物研发中心有限公司 | 重组组织型纤溶酶原激活剂及其制备方法与用途 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015062350A1 (zh) * | 2013-11-01 | 2015-05-07 | 广州联康医药科技有限公司 | 一种长效重组促卵泡激素及其应用 |
US10519212B2 (en) | 2013-11-01 | 2019-12-31 | Guangzhou Vbio Pharma Co., Ltd. | Long-acting recombinant follicle-stimulating hormone and use thereof |
WO2015062349A1 (zh) * | 2013-11-01 | 2015-05-07 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
US11472863B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof |
WO2018032785A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | 人成纤维细胞生长因子21融合蛋白及其制备方法与用途 |
WO2018032786A1 (zh) * | 2016-08-19 | 2018-02-22 | 安源医药科技(上海)有限公司 | 人凝血因子ix融合蛋白及其制备方法与用途 |
CN107759696A (zh) * | 2016-08-19 | 2018-03-06 | 安源医药科技(上海)有限公司 | 人白介素7融合蛋白及其制备方法 |
CN107759697A (zh) * | 2016-08-19 | 2018-03-06 | 安源生物科技(上海)有限公司 | 制备融合蛋白的方法 |
US11833212B2 (en) | 2016-08-19 | 2023-12-05 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
US11471513B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
AU2017431494B2 (en) * | 2017-09-15 | 2021-04-15 | Beijing Vjt Bio Co., Ltd. | Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof |
US11299527B2 (en) | 2017-09-15 | 2022-04-12 | Beijing Vjt Bio Co., Ltd. | Long-acting recombinant porcine FSH fusion protein and preparation method and application thereof |
WO2019051954A1 (zh) * | 2017-09-15 | 2019-03-21 | 北京伟杰信生物科技有限公司 | 长效重组猪fsh融合蛋白及其制备方法与应用 |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
CN113336831A (zh) * | 2020-07-24 | 2021-09-03 | 上海延立药业有限公司 | 一种用于开发新冠病毒疫苗的长效重组糖蛋白 |
CN114807231A (zh) * | 2022-06-28 | 2022-07-29 | 鲁东大学 | 鱼类促卵泡激素体细胞基因转移载体及其构建方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
US10023624B2 (en) | 2018-07-17 |
US20170174736A1 (en) | 2017-06-22 |
WO2015062349A1 (zh) | 2015-05-07 |
CN103539860B (zh) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103539860B (zh) | 一种长效重组人促卵泡激素融合蛋白 | |
CN103539861B (zh) | 长效重组人促卵泡激素融合蛋白 | |
CN103539862B (zh) | 一种长效重组促卵泡激素及其应用 | |
CN103554268B (zh) | 长效重组促卵泡激素及其应用 | |
CN102448991B (zh) | 分离的激动剂型抗edar单克隆抗体的制备 | |
US20220315658A1 (en) | Anti-pd-l1 single-domain antibody and derivatives and use thereof | |
CN103897064B (zh) | 长效重组人绒促性素融合蛋白 | |
CN103930134B (zh) | 长效促黄体激素(lh)化合物 | |
CN103554269B (zh) | 重组猪促卵泡激素融合蛋白 | |
CN106256835A (zh) | 高糖基化人生长激素融合蛋白及其制备方法与用途 | |
JP7153726B2 (ja) | Hm-3融合タンパク質及びその適用 | |
CN110003328A (zh) | 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法 | |
CN106117370A (zh) | 高糖基化Exendin‑4及其类似物的融合蛋白、其制备方法和用途 | |
CN106008722B (zh) | 一种重组β-hNGF-Fc融合蛋白、制备方法及用途 | |
CN103732240B (zh) | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 | |
CN103804498B (zh) | 长效重组绒促性素及其应用 | |
CN102146121A (zh) | 一种含有oxt拮抗剂药物的生产工艺 | |
CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
CN102936288A (zh) | 促红细胞生成素模拟肽融合蛋白及突变体 | |
RU2669787C2 (ru) | Средство для лечения заболевания, сопровождающегося отеком макулы вследствие повышенной экспрессии VEGF-A | |
CN116057071B (zh) | 重组灵芝免疫调节蛋白新突变体及其应用 | |
CN103044554A (zh) | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 | |
CN107001445A (zh) | 3型金属蛋白酶组织抑制剂(timp‑3)的变体、组合物及方法 | |
CN118126181A (zh) | 人和猴交叉种属抗ccr8膜蛋白抗体 | |
CN103819542A (zh) | 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
DD01 | Delivery of document by public notice |
Addressee: Guangzhou Youliankang Pharmaceutical Technology Co., Ltd. Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Hou Yongmin Document name: Notification of Passing Examination on Formalities |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161109 Address after: 510703, No. 9, Tung Shing Street, Guangzhou economic and Technological Development Zone, Guangdong, China Patentee after: Guangzhou best Biotechnology Co., Ltd. Address before: 510663 1 spire mountain road, Science Town, Guangzhou hi tech Industrial Development Zone, Guangdong Patentee before: Guangzhou Youliankang Pharmaceutical Technology Co., Ltd. |